Editas Medicine (EDIT) Net Cash Flow (2015 - 2025)

Editas Medicine (EDIT) has 11 years of Net Cash Flow data on file, last reported at $25.9 million in Q3 2025.

• On a quarterly basis, Net Cash Flow fell 17.5% year-over-year to $25.9 million in Q3 2025; TTM through Dec 2025 was $32.9 million, a 317.04% increase from a year earlier, with the FY2024 full-year figure at $7.9 million, up 144.15% from the prior year.
• Net Cash Flow for Q3 2025 stood at $25.9 million, up from -$150000.0 in the prior quarter.
• Over the last five years, Net Cash Flow for EDIT reached as high as $215.2 million in Q1 2021 and fell as low as -$138.3 million in Q3 2023.
• Historically, Net Cash Flow has averaged $1.3 million across 5 years, with a median of -$150000.0 in 2025.
• Across the five-year window, Net Cash Flow jumped 4804.61% in 2021 and slumped 434.79% in 2023, its largest moves.
• Year by year, Net Cash Flow stood at -$56.4 million in 2021, then retreated by 22.74% to -$69.2 million in 2022, then jumped by 159.43% to $41.1 million in 2023, then declined by 13.15% to $35.7 million in 2024, then decreased by 27.47% to $25.9 million in 2025.
• Per Business Quant data, the three most recent Net Cash Flow figures were $25.9 million in Q3 2025, -$150000.0 in Q2 2025, and $7.2 million in Q1 2025.